Tests CT1390B cell therapy in adults with relapsed or refractory acute myeloid leukemia
Tests CT1390B, a modified immune cell treatment, in adults with returning acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 whose acute myeloid leukemia (AML) has come back or did not respond to treatment, and whose leukemia cells are CLL-1 positive.
- Age
- 18-70 years
- Sex
- Men and women
- Disease stage
- Relapsed or refractory acute myeloid leukemia, CLL-1 positive. Bone marrow blasts at least 5% by morphology. Expected survival over 12 weeks. ECOG score 0-2.
- Earlier treatment
- People who had CAR-T therapy, a stem cell transplant within 12 weeks, or earlier immunotherapy aimed at CLL-1 cannot join.
- Biomarker or test result
- CLL-1 positive leukemia. Heart pumping (LVEF) above 50%. Liver, kidney and blood clotting tests must be within the limits set in the record.
Main reasons for not taking part
- Acute promyelocytic leukemia, BCR-ABL positive leukemia or active leukemia in the central nervous system
- History of epilepsy or other central nervous system disease
- Previous CAR-T therapy or earlier immunotherapy aimed at CLL-1
- Active graft-versus-host disease (GVHD), or steroids for GVHD
- HIV, syphilis, active hepatitis B or active hepatitis C infection
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07441980, who can take part
Where in China
- Institute of Hematology & Blood Diseases Hospital, ChinaTianjin, ChinaContact: Ying Wang, DrNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07441980
- Record updated
- 2 March 2026
- Original description
A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid LeukemiaRead full original descriptionShow less
A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Inclusion: Age 18-70 years (inclusive), male or female; Relapsed or refractory acute myeloid leukemia definitively diagnosed as CLL-1 positive according to the WHO 2022 classification; Bone marrow blast percentage ≥5% by morphology; Estimated survival > 12 weeks; ECOG score 0-2; Participants should meet the following test results (no ongoing supportive care); Left ventricular ejection fraction (LVEF) > 50%; ALT≤ 2.5 × ULN, AST ≤ 2.5 × ULN, total bilirubin ≤ 2 × ULN; ALT≤ 5 × ULN, AST ≤ 5 × ULN, total bilirubin ≤ 3 × ULN, if the liver is involved; Endogenous creatinine clearance ≥ 30 mL/min (creatinine clearance calculated using the Cockcroft-Gault formula); Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN and prothrombin time (PT) ≤ 1.5 × ULN.
Exclusion: Participants who have previously received autologous or allogeneic CAR-T therapy; Participants who have received autologous stem cell transplantation or allogeneic stem cell transplantation within 12 weeks; Participants who have received prior immunotherapy targeting CLL-1; Participant has clinically significant active GVHD or is receiving systemic corticosteroids for GVHD; History of myocardial infarction, coronary artery bypass grafting, or unstable angina within 6 months prior to Lymphodepleting Chemotherapy; Participants with a history of epilepsy or other central nervous system disease; Participant has any of the following at screening:; 1)Active, uncontrolled systemic infection or requiring intravenous anti-infective agents 2)Any of the following cardiac conditions, including:; New York Heart Association Class III-IV heart failure; History of uncontrolled arrhythmia of significant clinical significance (as judged by the investigator), such as ventricular arrhythmia; History of severe non-ischemic cardiomyopathy; Other cardiac disease that the investigator believe could jeopardize the participant 's well-being or compromise participation in this clinical trial; 3) Active bleeding of clinical significance as judged by the investigator 4)Requiring supplemental oxygen to maintain oxygen saturation> 92% 5)Patients with severe chronic obstructive pulmonary disease (COPD) or other lung diseases that cannot tolerate CAR-T treatment as judged by the investigator 8. Has HIV, syphilis infection, active hepatitis B virus infection (HBsAg positive and HBV-DNA above the detection limit), or active hepatitis C virus infection (HCV antibody and HCV-DNA positive); Participants were diagnosed with acute promyelocytic leukemia (APL) BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), active central nervous system leukemia.